ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 259 filers reported holding ACCELERON PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $8,493,000 | +35.0% | 49,352 | -1.5% | 0.01% | +37.5% |
| Q2 2021 | $6,289,000 | -12.6% | 50,114 | -5.6% | 0.01% | -20.0% |
| Q1 2021 | $7,197,000 | -1.5% | 53,069 | -7.1% | 0.01% | 0.0% |
| Q4 2020 | $7,306,000 | +12.2% | 57,101 | -1.3% | 0.01% | 0.0% |
| Q3 2020 | $6,513,000 | +21.8% | 57,880 | +3.1% | 0.01% | +11.1% |
| Q2 2020 | $5,347,000 | -16.3% | 56,124 | -21.0% | 0.01% | -30.8% |
| Q1 2020 | $6,388,000 | +73.3% | 71,076 | +2.2% | 0.01% | +116.7% |
| Q4 2019 | $3,687,000 | +38.8% | 69,536 | +3.4% | 0.01% | +20.0% |
| Q3 2019 | $2,656,000 | -0.6% | 67,236 | +3.4% | 0.01% | 0.0% |
| Q2 2019 | $2,672,000 | -2.9% | 65,050 | +10.0% | 0.01% | 0.0% |
| Q1 2019 | $2,753,000 | +18.5% | 59,113 | +10.8% | 0.01% | 0.0% |
| Q4 2018 | $2,323,000 | +11.0% | 53,334 | +45.8% | 0.01% | +25.0% |
| Q3 2018 | $2,093,000 | +13.1% | 36,577 | -4.1% | 0.00% | 0.0% |
| Q2 2018 | $1,850,000 | +28.4% | 38,122 | +3.4% | 0.00% | +33.3% |
| Q1 2018 | $1,441,000 | -9.4% | 36,854 | -1.7% | 0.00% | 0.0% |
| Q4 2017 | $1,591,000 | +10.6% | 37,484 | -2.7% | 0.00% | 0.0% |
| Q3 2017 | $1,438,000 | +27.1% | 38,532 | +3.5% | 0.00% | 0.0% |
| Q2 2017 | $1,131,000 | +32.4% | 37,217 | +15.3% | 0.00% | +50.0% |
| Q1 2017 | $854,000 | +8.0% | 32,272 | +4.1% | 0.00% | 0.0% |
| Q4 2016 | $791,000 | -20.6% | 30,988 | +12.5% | 0.00% | -33.3% |
| Q3 2016 | $996,000 | +8.4% | 27,534 | +1.8% | 0.00% | 0.0% |
| Q2 2016 | $919,000 | +47.5% | 27,034 | +14.6% | 0.00% | +50.0% |
| Q1 2016 | $623,000 | -38.1% | 23,593 | +14.3% | 0.00% | -33.3% |
| Q4 2015 | $1,007,000 | +111.1% | 20,643 | +7.7% | 0.00% | +50.0% |
| Q3 2015 | $477,000 | -19.3% | 19,168 | +2.6% | 0.00% | 0.0% |
| Q2 2015 | $591,000 | +0.3% | 18,685 | +20.8% | 0.00% | 0.0% |
| Q1 2015 | $589,000 | +18.3% | 15,470 | +21.1% | 0.00% | +100.0% |
| Q4 2014 | $498,000 | +23.6% | 12,770 | -4.1% | 0.00% | 0.0% |
| Q3 2014 | $403,000 | -14.1% | 13,320 | -3.6% | 0.00% | 0.0% |
| Q2 2014 | $469,000 | – | 13,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |